MOR-106

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMOR-106
Drug Alias NameMOR-106
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunomodulatorsInterleukin-17 inhibitors
TargetsInterleukin-17
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUkraine +[11
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGalapagos NvMorphosys Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMorphosys AgGalapagos Nv
Active IndicationsN/A
Inactive IndicationsDermatitis, Atopic

Other Information

ATC CodeN/A
Related LinksN/A